PRELIMINARY-OBSERVATIONS ON DANAZOL THERAPY OF SYSTEMIC LUPUS-ERYTHEMATOSUS - EFFECTS ON DNA ANTIBODIES, THROMBOCYTOPENIA AND COMPLEMENT

  • 1 January 1983
    • journal article
    • research article
    • Vol. 10  (5) , 682-687
Abstract
Seven patients with systemic lupus erythematosus (SLE) were treated with Danazol [danocrine] in a controlled study. Phenomena observed in some patients treated with Danazol were a decrease in immunoglobulins and antibodies to native DNA, increases in serum complement and platelets, and clinical improvement. Ineffective drug trials were associated with increasing disease activity. Drug side effects were minimal. The drug may have an ameliorative effect on mildy active SLE patients and sometimes a marked effect on thrombocytopenia. Further evaluation of Danazol appears to be warranted for these types of patients but not for treatment of acute or severe forms of the disease.